HUSSEIN MOUSTAPHA ALI-AHMAD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology LANSING, MI NPI 1821262676
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology MI NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$2,838.15
- Category: General Payments
- Program years: PY2018–2024
- Record count: 132
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,014.83 across 52 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,014.83 | 52 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $222.58 | 14 |
| Daiichi Sankyo Inc. | $79.29 | 3 |
| ABBVIE INC. | $73.48 | 3 |
| Celgene Corporation | $70.85 | 3 |
| Lilly USA, LLC | $61.04 | 3 |
| EISAI INC. | $42.26 | 2 |
| Janssen Biotech, Inc. | $41.20 | 2 |
| Acerta Pharma LLC | $35.71 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.13 | 1 |
| JAZZ PHARMACEUTICALS INC. | $32.82 | 1 |
| Merck Sharp & Dohme Corporation | $27.36 | 1 |
| GENZYME CORPORATION | $22.44 | 1 |
| SERVIER PHARMACEUTICALS LLC | $21.77 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $21.26 | 1 |
| PharmaEssentia USA Corporation | $20.27 | 1 |
| TAIHO ONCOLOGY, INC. | $19.98 | 1 |
| Astellas Pharma US Inc | $18.57 | 1 |
| Gilead Sciences, Inc. | $17.50 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.33 | 1 |
| Incyte Corporation | $17.23 | 1 |
| Genentech USA, Inc. | $16.62 | 1 |
| E.R. Squibb & Sons, L.L.C. | $16.61 | 1 |
| AVEO Pharmaceuticals, Inc. | $15.34 | 1 |
| GlaxoSmithKline, LLC. | $14.76 | 1 |
| PFIZER INC. | $13.77 | 1 |
| EMD Serono, Inc. | $13.63 | 1 |
| Invivyd Inc | $13.56 | 1 |
| ARRAY BIOPHARMA INC | $13.47 | 1 |
By program year
Records — PY2024 (52)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.